Akari Therapeutics (AKTX) Non-Current Assets (2012 - 2026)

Akari Therapeutics has disclosed Non-Current Assets across 14 years of filings, most recently posting $30.3 million for Q1 2026.

• Non-Current Assets for Q1 2026 came in at $30.3 million, down 36.36% year-over-year; the trailing twelve-month figure through Mar 2026 was $162.8 million (up 70.94% YoY), and the FY2025 annual result was $42.4 million, down 10.88% from the prior year.
• Non-Current Assets came in at $30.3 million for Q1 2026 at Akari Therapeutics, down from $42.4 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $47.6 million in Q4 2024 to a low of $14000.0 in Q4 2023.
• The 5-year median for Non-Current Assets is $42.4 million (2025), against an average of $32.3 million.
• Across the five-year window, Non-Current Assets jumped 339971.43% in 2024 and slumped 36.36% in 2026, its largest moves.
• Akari Therapeutics' Non-Current Assets stood at $17000.0 in 2022, then declined by 17.65% to $14000.0 in 2023, then surged by 339971.43% to $47.6 million in 2024, then declined by 10.88% to $42.4 million in 2025, then dropped by 28.59% to $30.3 million in 2026.
• The last three Non-Current Assets figures came in at $30.3 million (Q1 2026), $42.4 million (Q4 2025), and $42.4 million (Q3 2025), per Business Quant data.